T. Sun

发表

Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation

Yan Wang, Matthew B. Wilson, Yan Wang, 2001, Oncogene.

Janus kinase 2: a critical target in chronic myelogenous leukemia.

H. Kantarjian, Hui-Kuan Lin, R. Arlinghaus, 2006, Cancer research.

Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25

L. Dubeau, Minghong Wan, Tong Sun, 1999, Oncogene.

Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1

J. Minna, L. Ji, J. Roth, 2007, Oncogene.

Signal transduction pathways in Bcr-Abl transformed cells.

R. Arlinghaus, T. Sun, 2004, Cancer treatment and research.

Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD‐L1 expression and enhancing T‐lymphocyte tumor‐killing activity

Juan Ma, Yue‐Xiao Xing, Zhi Hong Zhang, 2021, Phytotherapy research : PTR.

Preparation and application of antibodies to phosphoamino acid sequences.

M. Campbell, R. Arlinghaus, T. Sun, 2001, Biopolymers.

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

J. Mestan, H. Kantarjian, J. Cortes, 2005, Clinical Cancer Research.

Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.

Z. Estrov, S. H. Lin, M. Talpaz, 2001, Cancer research.

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia

Jianliang Shen, Haifa Shen, Chaofeng Mu, 2016, Molecular Cancer Therapeutics.

BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor

H. Lin, R. Arlinghaus, A. Samanta, 2008, Oncogene.

Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia

J. Belmont, Hui-Kuan Lin, R. Arlinghaus, 2005, Oncogene.

Lipocalin 2 is required for BCR-ABL-induced tumorigenesis

Alan Aderem, J. Belmont, A. Aderem, 2008, Oncogene.

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

R. Arlinghaus, Xiaoyang Ling, Jiaxin Liu, 2003, Cancer research.

Advances in Brief Bcr and Abl Interaction : Oncogenic Activation of c-Abl by Sequestering Bcr 1

R. Arlinghaus, Xiaoyang Ling, Jiaxin Liu, 2003 .

The c-Myc Oncoprotein Interacts with Bcr

Yan Wang, R. Arlinghaus, T. Sun, 2003, Current Biology.

BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model

J. Belmont, Hui-Kuan Lin, R. Arlinghaus, 2001, Oncogene.

Effect of Reproductive Hormones on Ovarian Epithelial Tumors: II. Effect on Angiogenic Activity

Mimi C. Yu, P. Brooks, L. Dubeau, 2002, Cancer biology & therapy.

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells

Z. Estrov, H. Kantarjian, J. Cortes, 2005, Cancer.

Jak2 is involved in c-Myc induction by Bcr-Abl

Hui-Kuan Lin, R. Arlinghaus, S. Xie, 2002, Oncogene.

Preparation and Application of Polyclonal and Monoclonal Sequence‐Specific Anti‐Phosphoamino Acid Antibodies

R. Arlinghaus, T. Sun, 2003, Current protocols in protein science.

Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects

Y. Wang, R. Arlinghaus, T. Sun, 2008, Oncogene.

Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.

Yun Wu, Yan Wang, R. Arlinghaus, 2002, Cancer research.